Alnylam (ALNY) Q2 FY26 earnings call

Alnylam Pharmaceuticals delivered strong Q2 FY26 results, with AMVUTRA sales surpassing $1 billion for the first time, driven by robust first-line patient uptake. The company revised its full-year revenue guidance downwards due to a normalization of second-line demand for AMVUTRA, but expressed increased confidence in its long-term TTR leadership strategy, especially following competitive developments in the ATTR cardiomyopathy market. Management also highlighted ongoing pipeline progress and strategic AI collaborations.